

This article was downloaded by:

On: 28 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

Cyanothioacetamide in Heterocyclic Synthesis: A Novel Synthesis of Styrylpyridinethione, Styrylthieno[2,3-b]pyridine, Styrylpyrazolo[3,4-b]pyridine, Pyrido[2',3':3,4]pyrazolo[5,1-a]pyrimidine, Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine and Pyrido[3',2':4,5]thieno[3,2-d]-1,2,3-triazin-4-one Derivatives

Mohamed A. A. Elneairy^a

^a Cairo University, Giza, Egypt

Online publication date: 27 October 2010

To cite this Article Elneairy, Mohamed A. A.(2003) 'Cyanothioacetamide in Heterocyclic Synthesis: A Novel Synthesis of Styrylpyridinethione, Styrylthieno[2,3-b]pyridine, Styrylpyrazolo[3,4-b]pyridine, Pyrido[2',3':3,4]pyrazolo[5,1-a]pyrimidine, Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine and Pyrido[3',2':4,5]thieno[3,2-d]-1,2,3-triazin-4-one Derivatives', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 178: 10, 2201 – 2214

To link to this Article: DOI: 10.1080/713744557

URL: <http://dx.doi.org/10.1080/713744557>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**CYANTHIOACETAMIDE IN HETEROCYCLIC
SYNTHESIS: A NOVEL SYNTHESIS OF
STYRYLPYRIDINETHIONE,
STYRYLTHIENO[2,3-*b*]PYRIDINE,
STYRYLPYRAZOLO[3,4-*b*]PYRIDINE,
PYRIDO[2',3':3,4]PYRAZOLO[5,1-*a*]PYRIMIDINE,
PYRIDO[3',2':4,5]THIENO[3,2-*d*]PYRIMIDINE AND
PYRIDO[3',2':4,5]THIENO[3,2-*d*]-1,2,3-TRIAZIN-4-ONE
DERIVATIVES**

Mohamed A. A. Elneairy
Cairo University, Giza, Egypt

(Received December 2, 2002; accepted May 16, 2003)

*Synthesis of 6-styrylpyridinethione **6a–d**, 6-styrylthienopyridine **11a–d**, **15a–d**, pyrido[2',3':3,4]pyrazolo[5,1-*a*]pyrimidine **25**, **29**, pyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine **34**, and pyrido[3',2':4,5]thieno[3,2-*d*]-1,2,3-triazin-4-one **35** derivatives by the reaction of **4a, b**, **6a–d**, **22**, **33**, with **5a, b**, **9**, **13**, **23**, **27**, acetic anhydride and nitrous acid respectively.*

Keywords: Cyanthioacetamide; pyridopyrazolopyrimidine; pyridothienotriazinone; styrylpyrazolopyridine; styrylthienopyridine


The reactivity of 2- and 4-alkylpyridine was studied.^{1–3} This phenomenon has found extensive applications.^{4–7} In the last decades much attention have been devoted to the construction of new pyridine-2-thione and annelated derivatives on account of their reported biological activities.^{8–20} Various series of substituted pyridine-2-thione and their annelated derivatives are reported to have diverse biological activities as antibiotic,^{21,22} antiarteriosclerotic,²³ antibacterial,²⁴ antihyperglycemic,²⁵ antifungal,²⁶ agents and as inhibitors of the blood coagulation factor.²⁷ Also, thienopyridine derivatives have been reported to be useful as antibiotic,^{28–31} drug intermediates³² against endoparasiticides³³ and as antianaphylactics compounds.^{34,35} Moreover

Address correspondence to Mohamed A. A. Elneairy, Chemistry Department, Faculty of Science, Cairo University, Giza, Egypt. E-mail: elneairy@hotmail.com

some substituted thienopyridine have been reported to inhibit acetyl CoA-cholesterol O-acetyltransferase³⁶ the release of cerebral glutamate³⁷ smooth muscle cells proliferation³⁸ and the pressor response of angiotensin in rats.³⁹

RESULTS AND DISCUSSION


It has been found that compound **1a,b** reacted with acetylacetone (**2**) to give the final isolable reaction products **4a,b**. Compounds **4a,b** could be formed through the non-isolable intermediates **3a,b** via the Micheal addition of the methylene group of **2** to the double bond of **1a,b** and elimination of one molecule of water and one molecule of hydrogen under the experimental reaction conditions to give the cyclized products **4a,b** (cf. Scheme 1). The IR spectrum of **4a** showed the absorption bands of OH, NH, CN, and C=O groups. Moreover its mass spectrum gave the molecular ion peak at 284 which is exactly molecular weight of **4a**. From the above data compound **4a** could be formulated as 5-acetyl-3-cyano-4-(4-hydroxyphenyl)-6-methylpyridine-2-thione (**4a**) (cf. Scheme 1). Due to the reactivity of methyl group at 6 position in pyridine and presence of more than one active site, compounds **4a,b** were taking as starting materials for the present work to synthesis a new heterocyclic derivatives with expected biological activity. It has been found that the compound **4a** reacted with benzaldehyde (**5a**) and p-chlorobenzaldehyde (**5b**) to afford the reaction products **6a,b** and not **7a-d**.¹⁻³ The IR spectra of **6a,b** showed the absorption bands of nitrile at 2222, carbonyl at 1681. The ¹H-NMR of **6a,b** revealed the signals of styryl and aromatic protons at 6.83–7.65. Compounds **6a,b** could be formed via the condensation reaction between carbonyl group of aldehyde and methyl at pyridine¹⁻³ ring to give the final isolable reaction product corresponding to 6-styrylpyridine-2-thione derivatives **6a,b** (cf. Scheme 1 and Experimental). In the same manner compound **4b** reacted with **5a,b** to afford the corresponding 6-styrylpyridinethione **6c,d**. These reaction products could be formulated based on the elemental analyses and spectral data as **6a,b** previously prepared, all trials to cyclize the compounds **6a-d** into quinolinone-2-thione derivatives **8a-d** are failed. The structure of compounds **6a-d** were confirmed via the reaction of **6a-d** with halogenated compounds such as α -chloroacetone (**9**) and α -chloroacetamide (**13**). It has been found that compound **6a** reacted with chloroacetone (**9**) to yield the corresponding 6-styrylthieno[2,3-b]pyridine derivative **11a**. The IR of **11a** showed the absorption bands at 3201, 3101, and 1697 corresponding to NH₂ and C=O groups at pyridine ring and didn't show any absorption band for nitrile function. Compound **11a** could



6-19	Ar	Ar'
a	C ₆ H ₄ -p-OH	C ₆ H ₅
b	C ₆ H ₄ -p-OH	C ₆ H ₄ -p-Cl
c	C ₆ H ₄ -p-NMe ₂	C ₆ H ₅
d	C ₆ H ₄ -p-NMe ₂	C ₆ H ₄ -p-Cl

SCHEME 1

be formed via the addition of methylene group to the nitrile function of **10a**. Based on the above data compound **11a** could be formulated as 2,5-diacetyl-3-amino-6-styrylthieno[2,3-b]pyridine derivative. In the same manner compounds **6b–d** reacted with **9** to give the corresponding 6-styrylthieno[2,3-b]pyridine derivatives **11b–d** in respective manner. On the other hand compounds **6a–d** reacted with chloroacetamide (**13**). It has been found that compound **6a** reacted with **13** to give the corresponding 6-styrylthieno[2,3-b]pyridine derivative **15a**. The IR spectrum of **15a** showed the absorption bands of two amino groups at 3373, 3327, 3256, 3192. Moreover it's H-NMR spectrum revealed the signal corresponding to two amino, methyl, aromatic and styryl protons (cf. Experimental Part). In the same manner compounds **6b–d** reacted with **13** and gave the corresponding 6-styrylthieno[2,3-b]pyridine derivative **15b–d** respectively. Compounds **15a–d** were confirmed based on the elemental analyses and spectral data (cf. Scheme I and Experimental). Compounds **6a–d** were further reacted with hydrazine hydrate to give **18a–d**. It has been found that compound **6a** reacted with hydrazine hydrate to afford sulfur free compound corresponding to 6-styrylpyrazolo[3,4-b]pyridine derivative **18a**. The latter reaction product could be formed via the addition of hydrazino group of **17a** to the nitrile function. The IR spectrum of **18a** didn't show any absorption band corresponded to the nitrile function and show the newly born amino group. In the same manner compounds **6b–d** reacted with hydrazine hydrate to give the corresponding 6-styrylpyrazolo[3,4-b]pyridine derivatives **18b–d** respectively. Compounds **18b–d** could be confirmed based on the elemental analyses and spectral data (cf. Scheme 1 and Experimental). All trials to cyclize **11a–d**, **15a–d**, and **18a–d** to the corresponding thieno[2,3-b]quinolinone derivatives and pyrazolo[3,4-b]quinolinone derivatives **12a–d**, **16a–d** and **19a–d** were unsuccessful. The work was extended to prepare a new heterocyclic derivatives. It has been found that compounds **4a,b** reacted with hydrazine hydrate to give the corresponding pyrazolo[3,4-b]pyridine derivatives **21a,b**. Compound **21b** was taking as starting material for synthesis new heterocyclic moiety via the reaction with dimethylformamide dimethylacetal (DMF-DMA). It has been found that compound **21b** reacted with dimethylformamide dimethylacetal (DMF-DMA) in dry xylene to afford 3-(N,N-dimethylmethyleneamino)pyrazolo[3,4-b]pyridine derivative **22** (cf. Scheme 2). The IR spectrum of the latter reaction product showed a band at 3179 which corresponded to the NH group in pyrazole ring and didn't show any absorption band corresponding to the amino group which consumed in the reaction to give the imino group. Moreover it's H-NMR spectrum didn't reveal any signal corresponding to the amino group (cf. Scheme 2). Further elucidation of




SCHEME 2

compound **22** via the reaction with different active methylene containing compounds such as malononitrile (**23**), cyanothioacetamide (**26**) and ethyl cyanoacetate (**27**). It has been found that compound **22** reacted with **23** to give the corresponding pyrido[2',3':3,4]pyrazolo[5,1-a]pyrimidine derivative **25** via a) loss of one molecule of dimethylamine and b) addition of NH group of pyrazole to the nitrile function in **24**. The IR spectrum of **25** showed the newly born of amino group. Compound **25** could be also prepared via another route by the reaction of **22** with cyanothioacetamide (**26**) to afford the corresponding pyrido[2',3':3,4]pyrazolo[5,1-a]pyrimidine derivative **25** via loss one molecule of dimethylamine and one molecule of hydrogen sulphide. Compound **25** which prepared via this route was found to be identical as **25** previous

prepared in all aspects (melting point and mixed melting point) (cf. Scheme 2 and Experimental).

A third elucidation of compound **22** via its reaction with ethyl cyanoacetate (**27**) to give the corresponding pyrido[2',3':3,4]pyrazolo[5,1-a]pyrimidine derivative **29**. Compound **29** could be confirmed based on the elemental analysis and spectral data (cf. Scheme 2 and Experimental). The work was extended to prepare a new thieno[2,3-b]pyridine, pyrido[3'2':4,5]thieno[3,2-d]pyrimidine and pyrido-[3',2':4,5]thieno[3,2-d]-1,2,3-triazin-4-one derivatives. It has been found that compound **4a** reacted with **9** to give the corresponding thieno[2,3-b]pyridine derivative **31**. The IR spectrum of **31** showed the absorption bands at 3468, 3341 which corresponded to the amino group. Moreover it's H-NMR revealed the signal corresponded to the amino protons. Based on the above data compound **31** could be formulated as thieno[2,3-b]pyridine derivative (cf. Scheme 3 and Experimental).



SCHEME 3

On the other hand compound **4a** reacted with **13** to yield the 2-S-carbamoylmethylpyridine derivative **32** which could be cyclized via its boiling with alcoholic potassium hydroxide solution into thieno[2,3-b]pyridine derivative **33**. Compound **33** could be confirmed via the

reaction with acetic anhydride and nitrous acid to give the corresponding pyrido[3',2':4,5]thieno[3,2-d]pyrimidine and pyrido[3',2':4,5]thieno[3,2-d]-1,2,3-triazin-4-one derivatives **34** and **35** in respective manner. The structures of compounds **34** and **35** were confirmed based on the elemental analyses and spectral data (cf. Scheme 3 and Experimental). Compound **34** could be synthesized via another route by the reaction of **32** with acetic anhydride to give pyrido[3',2':4,5]thieno[3,2-d]pyrimidine derivative **34**. Compound **34** was formed via this route was found to be identical as **34** previously prepared (cf. Scheme 3 and Experimental).

EXPERIMENTAL

All melting points were measured on a Gallenkamp electrothermal melting point apparatus and are uncorrected. The infrared spectra were recorded in potassium bromide on a Pye Unicam SP 3-300 infrared and FT-IR 8101PC Shimadzu spectrophotometers. The ^1H NMR spectra were recorded in deuterated chloroform or dimethyl sulphoxide on a Varian Gemini 200 NMR and varian Mercury 300 MHz spectrometer using tetramethylsilane(TMS) as an internal reference; mass spectra were recorded on a GCMS-QP 1000 EX Shimadzu mass spectrometer at 70 eV. Elemental analysis were carried out at the Microanalytical Center of Cairo University, Giza, Egypt.

Compounds **1a,b**,⁴⁰ **4b**¹³ and **21b**¹³ were prepared according to the literature procedure.

Synthesis of Compounds **4a**, **6a-d**, **25**, and **29**

General Procedure

A solution of each of **1a**, **4a,b**, **22** (0.01 mmol) and **2**, **5a,b**, **23** (**26**), **27** (0.01 mmol) in ethanol (30 ml) and piperidine (0.5 ml) were heated under reflux for 5 h. The excess of the ethanol was evaporated in vacuo. The solids obtained were collected by filtration and crystallized from the proper solvent to give **4a**, **6a-d**, **25** and **29** respectively.

5-Acetyl-3-cyano-4-(4-hydroxyphenyl)-6-methylpyridine-2(1H)-thione (4a). Yellow crystals (75%, ethanol), m.p. 294–296°C; IR (cm^{-1}) ν 3244 (OH), 3101 (NH), 2229 (CN) and 1658 (CO). MS ($M = 89.7\%$, $M - 15 = 100\%$). Anal. for $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_2\text{S}$ (284) Calcd: C, 63.36, H, 4.25; N, 9.85; S, 11.28. Found: C, 63.00; H, 4.00; N, 9.60; S, 11.60.

5-Acetyl-3-cyano-4-(4-hydroxyphenyl)-6-styrylpyridine-2(1H)-thione (6a). Yellow crystals (75% ethanol), m.p. 226–228°C; IR (cm^{-1}) ν 3425

(OH), 3417 (NH), 2222 (CN), 1682 (C=O). Anal. for $C_{22}H_{16}N_2O_2S$ (372.45) Calcd: C, 70.95; H, 4.33; N, 7.52; S, 8.61. Found: C, 71.10; H, 4.10; N, 7.90; S, 8.70.

5-Acetyl-3-cyano-4-(4-hydroxyphenyl)-6-(4-chlorostyryl)pyridine-2-(1H)-thione (6b). Yellow crystals (80%, ethanol), m.p. 182–184°C; IR (cm^{-1}) ν 3420 (OH), 3209 (NH), 2206 (CN), 1682 (C=O); 1H NMR (DMSO) δ 1.78 (s, 3H, CH_3), 4.36 (brs, 1H, NH), 6.83–7.65 (m, 10H, ArH's and $CH=CH$) and 7.73 (s, 1H, OH). Anal. for $C_{22}H_{15}N_2O_2SCl$ (406.89) Calcd: C, 64.94; H, 3.72; N, 6.88; S, 7.88; Cl, 8.71. Found: C, 64.60; H, 3.90; N, 6.70; S, 8.10.

5-Acetyl-3-cyano-4-(4-N,N-dimethylaminophenyl)-6-styrylpyridine-2(1H)-thione (6c). Yellow crystals (75%, ethanol), m.p. 234–236°C; IR (cm^{-1}) ν 3230, (NH), 2210 (CN); 1678 (C=O); MS ($M = 100\%$, $M-15 = 31.1\%$). Anal. for $C_{24}H_{21}N_3OS$ (399.52) Calcd: C, 72.15; H, 5.30; N, 10.52; S, 8.03. Found: C, 72.40; H, 4.10; N, 10.50; S, 7.90.

5-Acetyl-3-cyano-4-(4-N,N-dimethylaminophenyl)-6-(4-chlorostyryl)-pyridine-2(1H)-thione (6d). Brown crystals (80%, ethanol), m.p. 282–284°C; IR (cm^{-1}) ν 3417 (NH), 2214 (CN), 1697 (C=O). Anal. for $C_{24}H_{20}N_3OSCl$ (433.96) Calcd: C, 66.43; H, 4.65; N, 9.68; S, 3.69; Cl, 8.17. Found: C, 66.30; H, 4.80; N, 9.90; S, 3.80; Cl, 8.30.

9-Acetyl-4-amino-8-methyl-10-(4-N,N-dimethylaminophenyl)pyrido-[2',3':3,4]pyrazolo-[5,1-a]pyrimidine-3-carbonitrile (25). Pale-green crystals (75%, ethanol), m.p. $>350^\circ C$; IR (cm^{-1}) ν 3433, 3271 (NH_2), 2214 (CN); 1682 (C=O); MS ($M = 98.04\%$, $M-15 = 100\%$). Anal. for $C_{21}H_{19}N_7O$ (385.43) Calcd: C, 65.44; H, 4.97; N, 25.44. Found: C, 65.30; H, 4.80; N, 25.70.

Ethyl-9-acetyl-4-amino-8-methyl-10-(4-N,N-dimethylaminophenyl)-pyrido[2',3':3,4]-pyrazolo[5,1-a]pyrimidine-3-carboxylate (29). Yellow crystals (75%, ethanol), m.p. 308–310°C; IR (cm^{-1}) ν 3402, 3232 (NH_2), 1689 (C=O); 1HNMR ($CDCl_3$) δ 1.37–1.44 (t, 3H, OCH_2CH_3), 1.64 (s, 2H, NH_2), 1.98 (s, 3H, CH_3 at pyridine), 2.70 (s, 3H, $COCH_3$), 3.07 (s, 6H, $N(Me)_2$), 4.37–4.48 (q, 2H, OCH_2CH_3) 6.78–7.53 (m, 4H, ArH's) and 8.91 (s, 1H, CH at pyrimidine). Anal. for $C_{23}H_{24}N_6O_3$ (432.00) Calcd: C, 63.88; H, 5.59; N, 19.43. Found: C, 63.60; H, 5.80; N, 19.50.

Synthesis of Compounds 11a–d and 31

General Procedure

A solution of each of **6a–d** and **4a** (0.01 mmol) in sodium ethoxide (0.01 mmol) prepared from 0.01 mmol sodium metal in 30 ml ethanol and chloroacetone (**9**) (0.01 mmol) was heated under reflux for 5 h. Cool

poured on to ice bath, then acidified with hydrochloric acid. The solid products were collected by filtration, washed with water and crystallized from the proper solvent to give **11a–d** and **31** respectively.

*2,5-Diacetyl-3-amino-4-(4-hydroxyphenyl)-6-styrylthieno[2,3-*b*]pyridine (11a)*. White crystals (60% ethanol/DMF), m.p. >330°C; IR (cm⁻¹) ν 3417 (OH), 3201, 3101 (NH₂), 1705, 1674 (two C=O). Anal. for C₂₅H₂₀N₂O₃S (428.51) Calcd: C, 70.07; H, 4.70; N, 6.54; S, 7.48. Found: C, 70.20; H, 4.50; N, 6.40; S, 7.20.

*2,5-Diacetyl-3-amino-4-(4-hydroxyphenyl)-6-(4-chlorostyryl)thieno[2,3-*b*]pyridine (11b)*. Yellow crystal (60% ethanol), m.p. 308–310°C; IR (cm⁻¹) ν 3471 (OH), 3310, 3125 (NH₂), 1705 (C=O). ¹H NMR (DMSO) δ 2.1 (s, 3H, COCH₃ at pyridine), 2.38 (s, 3H, COCH₃ at thiophene), 3.58 (s, 2H, NH₂), 6.95–7.99 (m, 10H, ArH's and CH=CH) and 10.1 (s, 1H, OH). Anal. for C₂₅H₁₉N₂O₃SCl (462.96) Calcd: C, 64.86; H, 4.14; N, 6.05; S, 6.93; Cl, 7.66. Found: C, 64.70; H, 4.30; N, 6.3; S, 7.10; Cl, 7.30.

*2,5-Diacetyl-3-amino-4-(4-*N,N*-dimethylaminophenyl)-6-styrylthieno[2,3-*b*]pyridine (11c)*. Orange crystals (55% ethanol), m.p. 281–283°C; IR (cm⁻¹) 3464, 3320 (NH₂), 1705 (C=O); ¹H NMR (DMSO) δ 2.1 (s, 3H, COCH₃ at pyridine), 2.38 (s, 3H, COCH₃ at thiophene), 3.37 (s, 6H, N(CH₃)₂), 6.51 (brs, 2H, NH₂) and 6.85–8.00 (m, 11H, ArH's and CH=CH). Anal. for C₂₇H₂₅N₃O₂S (455.58) Calcd: C, 71.18; H, 5.53; N, 9.22; S, 7.04. Found: C, 71.20; H, 5.30; N, 9.5; S, 7.30.

*2,5-Diacetyl-3-amino-4-(4-*N,N*-dimethylaminophenyl)-6-(4-chlorostyryl)thieno[2,3-*b*]pyridine (11d)*. Brown crystals (60% ethanol), m.p. >340°C; IR (cm⁻¹) ν 3425, 3351 (NH₂), 1702 (C=O). Anal. for C₂₇H₂₄N₃O₂SCl (490.03) Calcd: C, 66.18; H, 4.94; N, 8.58; S, 6.54; Cl, 7.23. Found: C, 66.30; H, 4.70; N, 8.70; S, 6.80; Cl, 6.90.

*2,5-Diacetyl-3-amino-4-(4-hydroxyphenyl)-6-methylthieno[2,3-*b*]pyridine (31)*. Yellow crystals (60% ethanol), m.p. 308–310°C; IR (cm⁻¹) ν 3500 (OH), 3468, 3341 (NH₂), 1697, 1632 (two C=O). ¹H NMR (DMSO) δ 2.00 (s, 3H, COCH₃ at pyridine), 2.35 (s, 3H, COCH₃ at thiophene), 6.46 (brs, 2H, NH₂) 6.97–7.21 (m, 4H, ArH's) and 10.34 (s, 1H, OH). Anal. For. C₁₈H₁₆N₂O₃S (340.40) Calcd: C, 63.51; H, 4.74; N, 8.23; S, 9.42. Found: C, 63.40; H, 4.90; N 8.50; S, 9.20.

Synthesis of 15a–d and 32

General Procedure

A solution of each of **6a–d** and **4a** (0.01 mmol) in sodium ethoxide (0.01 mmol prepared from 0.01 mmol sodium metal in 30 ml ethanol)

and chloroacetamide (**13**) (0.01 mmol) was heated under reflux for 5 h. It was cooled by being poured into an ice-bath, then acidified with hydrochloric acid. The solid products were collected by filtration, washed with water, and crystallized from the proper solvent to give **15a–d** and **32** respectively.

5-Acetyl-3-amino-2-carbamoyl-4-(4-hydroxyphenyl)-6-styrylthieno[2,3-b]pyridine (15a). Yellow crystals (65%, ethanol), m.p. 256–258°C; IR (cm⁻¹) ν 3483 (OH), 3373, 3327, 3250, 3192 (two NH₂), 1697, 1654 (two C=O); ¹H NMR (DMSO) δ 2.01 (s, 3H, COCH₃), 4.1 (s, 2H, NH₂), 6.94–8.22 (m, 13H, ArH's, NH₂ and CH=CH) and 7.88 (s, 1H, OH). MS (M = 80.2%, M-18 = 30.9%, M-44 = 100%). Anal. for C₂₄H₁₉N₃O₃S (429.50) Calcd: C, 67.12; H, 4.46; N, 9.78; S, 7.47. Found: C, 67.1; H, 4.2; N, 10.00; S, 7.40.

5-Acetyl-3-amino-2-carbamoyl-4-(4-hydroxyphenyl)-6-(4-chlorostyryl)thieno[2,3-b]pyridine (15b). Brown crystals (55%, ethanol), m.p. 319–321°C; IR (cm⁻¹) ν 3483 (OH), 3373, 3327, 3250, 3192 (two NH₂), 1697, 1654 (two C=O). Anal. for C₂₄H₁₈N₃O₃SCl (463.95) Calcd: C, 62.13; H, 3.91; N, 9.06; S, 6.91; Cl, 7.64. Found: C, 62.30; H, 4.00; N, 9.20; S, 6.70; Cl, 7.30.

5-Acetyl-3-amino-2-carbamoyl-4-(4-N,N-dimethylaminophenyl)-6-styrylthieno[2,3-b]pyridine (15c). Yellow crystals (65%, ethanol), m.p. 312–314°C; IR (cm⁻¹) ν 3472, 3356, 3210, 3180 (two NH₂), 1690 (C=O); ¹H NMR (CDCl₃) δ 1.95 (s, 3H, COCH₃), 3.96 (s, 2H, NH₂), 3.05 (s, 6H, N(Me)₂) and 6.74–8.16 (m, 13H, ArH's, NH₂ and CH=CH). Anal. for C₂₆H₂₄N₄O₂S (456.57) Calcd: C, 68.40; H, 5.30; N, 12.27; S, 7.02. Found: C, 68.10; H, 5.6; N, 13.00; S, 7.30.

5-Acetyl-3-amino-2-carbamoyl-4-(4-N,N-dimethylaminophenyl)-6-(4-chlorostyryl)thieno[2,3-b]pyridine (15d). Brown crystals (60%, ethanol), m.p. >330°C; IR (cm⁻¹) ν 3460, 3350, 3220, 3190 (two NH₂), 1688 (two C=O). Anal. for C₂₆H₂₃N₄O₂SCl (491.02) Calcd: C, 63.60; H, 4.72; N, 11.41; S, 6.53; Cl, 7.22. Found: C, 63.50; H, 4.50; N, 11.20; S, 6.20; Cl, 7.00.

5-Acetyl-2-carbamoylmethylthio-3-cyano-4-(4-hydroxyphenyl)-6-methylpyridine (32). Yellow crystals (70%, ethanol), m.p. 226–228°C; IR (cm⁻¹) ν 3456 (OH), 3364, 3295 (NH₂), 2222 (CN), 1682 (C=O); ¹H NMR (DMSO) δ 1.98 (s, 3H, CH₃), 2.53 (s, 3H, COCH₃), 4.1 (s, 2H, SCH₂CONH₂), 6.98–7.28 (m, 4H, ArH's), 7.77 (s, 1H, OH), 10.2 (brs, 4H, two NH₂). Anal. for C₁₇H₁₅N₃O₃S (341.39) Calcd: C, 59.81; H, 4.43; N, 12.31; S, 9.39. Found: C, 59.00; H, 4.70; N, 12.20; S, 9.50.

Synthesis of 18a–d and 21a

A solution of each of **6a–d** and **4a** (0.01 mmol) in hydrazine hydrate (5 ml) and ethanol (20 ml) was heated under reflux for 5 h. The solid products that formed were collected by filtration and crystallized from the proper solvent to give **18a–d** and **21a** respectively.

*5-Acetyl-3-amino-4-(4-hydroxyphenyl)-6-styrylpyrazolo[3,4-*b*]pyridine (18a)*. Brown crystals (70%, dilute ethanol), m.p. 201–203°C; IR (cm⁻¹) ν 3460 (OH), 3364, 3294, 3217 (NH₂ and NH), 1690 (C=O). Anal. for C₂₂H₁₈N₄O₂ (370.41) Calcd; C, 71.34; H, 4.90; N, 15.13. Found: C, 71.50, H, 4.80; N, 15.3.

*5-Acetyl-3-amino-4-(4-hydroxyphenyl)-6-(4-chlorostyryl)pyrazolo[3,4-*b*]pyridine (18b)*. Brown (70%, dilute ethanol), m.p. 203–205°C; IR (cm⁻¹) ν 3460 (OH), 3430, 3294, 3194 (NH₂ and NH), 1682 (C=O). ¹H NMR (DMSO) δ 1.58 (s, 2H, NH₂), 1.93 (s, 3H, COCH₃), 6.71–7.23 (m, 10H, ArH's and CH=CH), 7.44 (s, 1H, OH) and 9.54 (s, 1H, NH). Anal. for C₂₂H₁₇N₄O₂Cl (404.86) Calcd; C, 65.27; H, 4.23; N, 13.84; Cl, 8.76. Found: C, 65.50; H, 4.50; N, 14.00; Cl, 8.60.

*5-Acetyl-3-amino-4-(4-*N,N*-dimethylaminophenyl)-6-styrylpyrazolo[3,4-*b*]pyridine (18c)*. Yellow crystals (70%, ethanol), m.p. 276–278°C, IR (cm⁻¹) ν 3425, 3310, 3140 (NH₂ and NH) (C=O). ¹H NMR (CDCl₃) δ 1.78 (s, 3H, COCH₃), 2.98 (s, 6H, N(Me)₂), 5.79 (brs, 1H, NH), 6.71–7.39 (m, 13H, ArH's, NH₂ and CH=CH). Anal. for C₂₄H₂₃N₅O (397.48) Calcd; C, 72.52; H, 5.83; N, 17.62. Found: C, 72.50; H, 6.00; N, 17.90.

*5-Acetyl-3-amino-4-(4-*N,N*-dimethylaminophenyl)-6-(4-chlorostyryl)-pyrazolo[3,4-*b*]pyridine (18d)*. Yellow (70%, dilute ethanol), m.p. 280–282°C; IR (cm⁻¹) ν 3456, 3302, 3194 (NH₂ and NH) (1689 (C=O). ¹H NMR (DMSO) δ 1.94 (s, 3H, COCH₃), 3.00 (s, 6H, NMe₂), 4.45 (s, 2H, NH₂), 6.85–7.21 (m, 10H, ArH's and CH=CH) and 12.21 (s, 1H, NH). Anal. for C₂₄H₂₂N₅OCl (431.93) Calcd; C, 66.74; H, 5.13; N, 16.21; Cl, 8.21. Found: C, 66.50; H, 4.80; N, 15.90; Cl, 8.50.

*5-Acetyl-3-amino-4-(4-hydroxyphenyl)-6-methylpyrazolo[3,4-*b*]pyridine (21a)*. Yellow (70%, ethanol), m.p. 310–312°C; IR (cm⁻¹) ν 3460 (OH), 3294, 3194 (NH₂ and NH), 1683 (C=O). Anal. for C₁₅H₁₄N₄O₂ (282.3) Calcd; C, 63.82 H, 5.00; N, 19.85. Found: C, 63.50, H, 4.80; N, 20.00.

Synthesis of 22

A solution of **4b** (0.01 mmol) and dimethylformamide dimethylacetal (DMF-DMA 0.01 mmol) in dry xylene (30 ml) was heated under reflux

for 4 h. The excess of xylene evaporated in vacuo. The residue was triturated with petroleum ether the solid obtained was collected by filtration and crystallized from ethanol to give **22**.

5-Acetyl-4-(4-N,N-dimethylaminophenyl)-6-methyl-3-(N,N-dimethylaminomethyleneamino)pyrazolo[3,4-b]pyridine (22). Yellow (70%, ethanol), m.p. 248–250°C; IR (cm⁻¹) ν 3179 (NH) 1690 (C=O); ¹H NMR (DMSO) δ 1.90 (s, 3H, CH₃), 2.72 (s, 3H, COCH₃), 2.93 (s, 6H, NMe₂), 2.97 (s, 6H, NMe₂), 6.74–7.23 (m, 4H, ArH's), 7.72 (s, 1H, N=C_H-NMe₂) and 12.60 (s, 1H, NH) Anal. for C₂₀H₂₄N₆O (364.45) Calcd: C, 65.91 H, 6.64; N, 23.06. Found: C, 66.00; H, 6.40; N, 22.90.

Synthesis of 33

A solution of **32** (1 mmol), potassium hydroxide (2 mmol) and ethanol (30 ml) was heated under reflux for 4 h. It was cooled and acidified with concentrated hydrochloric acid. The solid obtained was collected by filtration and crystallized from ethanol to give **33**.

5-Acetyl-3-amino-2-carbmoyl-4-(4-hydroxyphenyl)-6-methylthienof[2,3-b]pyridine (33). Yellow crystals (75% ethanol), m.p. 255–257°C; IR (cm⁻¹) ν OH (3417), 3390, 3280 (two NH₂), 1682, 1643 (two C=O). Anal. For. C₁₇H₁₅N₃O₃S (341.39) Calcd: C, 59.81; H, 4.43; N, 12.31; S, 9.39. Found: C, 60.00; H, 4.70; N, 12.20; S, 9.50.

Synthesis of 34

A solution of **32** or **33** (0.01 mmol) in acetic anhydride (20 ml) was heated under reflux for 4 h. The solid obtained was collected by filtration and crystallized from acetic acid to give **34**.

8-Acetyl-2,7-dimethyl-9-(4-hydroxyphenyl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-one (34). White crystals (55%, acetic acid), m.p. 328–330°C; IR (cm⁻¹) ν 3448 (OH), 3385 (NH), 1705, 1651 (two C=O). Anal. for C₁₉H₁₅N₃O₃S (365) Calcd: C, 62.45; H, 4.14; N, 11.50; S, 8.77. Found: C, 62.40; H, 3.90; N, 11.20; S, 9.90.

Synthesis of 35

To a stirred cold solution (0–5°C) of **33** (1 mmol) in water (10 ml) and concentrated hydrochloric acid (5 ml), a solution of sodium nitrite (0.23 g in 5 ml of water) was added during 30 min. Stirring was continued for 40 min at –5°C. The reaction mixture was then allowed to stand at 0–5°C for 3 h. The solid obtained was collected by filtration and crystallized from ethanol to give **35**.

7-Acetyl-8-methyl-9-(4-hydroxyphenyl)pyrido[3',2':4,5]thieno[3,2-d]-1,2,3-triazin-4-one (35). Yellow crystals (55%, ethanol), m.p. >320°C; IR (cm⁻¹) ν 3418 (OH), 3320 (NH), 1697, 1651 (two C=O). Anal. for C₁₇H₁₂N₄O₃S (352.37) Calcd: C, 57.95; H, 3.43; N, 15.90; S, 9.10. Found: C, 58.10; H, 3.70; N, 16.10; S, 8.90.

REFERENCES

- [1] A. R. Kataritzky, *Handbook of Heterocyclic Chemistry* (Pergamon Press, Oxford, 1985).
- [2] J. A. Joule and G. F. Smith, *Heterocyclic Chemistry* (Van Nostrand Reinhold Company Ltd., London, 1978), p. 42.
- [3] S. A. S. Ghozlan, *Sulfur Letters*, **13**, 27 (1991).
- [4] S. A. S. Ghozlan, M. H. Mohamed, A. Y. Soliman, and H. Bakeer, *Gazz. Chem. Ital.*, **119** (1989).
- [5] R. Merckx, *Bull. Soc. Chem. Belg.*, **58**, 460 (1949).
- [6] A. J. Boulton and A. McKillp, *Comprehensive Heterocyclic Chemistry*, edited by A. R. Katritzky and R. Rees (Pergamon Press, Oxford, 1984), vol. 2, p. 50.
- [7] M. H. Elnagdi, F. M. Abdel-Razik, N. S. Ibrahim, and A. W. Erian, *Tetrahedron*, **45**, 3597 (1989).
- [8] F. A. Attaby, S. M. Eldin, W. M. Basyouni, and M. A. A. Elneairy, *Phosphorus, Sulfur and Silicon*, **108**, 31 (1996).
- [9] F. A. Attaby, S. M. Eldin, W. M. Basyouni, and M. A. A. Elneairy, *Phosphorus, Sulfur and Silicon*, **119**, 1 (1996).
- [10] F. A. Attaby, S. M. Eldin, and M. A. A. Elneairy, *J. Chem. Res. (M)*, **10**, 632; (*S*), **10**, 2754 (1998).
- [11] S. M. Eldin, F. A. Attaby, and M. A. A. Elneairy, *Heteroatom Chem.*, **9**, 571 (1998).
- [12] M. A. A. Elneairy, T. M. Abdel-Rahman, and A. M. Hammad, *J. Chem. Res. (M)*, **11**, 2834; (*S*) **11**, 684 (1998).
- [13] M. A. A. Elneairy, *Phosphorus, Sulfur, and Silicon*, **148**, 189 (1999).
- [14] F. A. Attaby, M. A. A. Elneairy, and M. S. Elsayed, *Phosphorus, Sulfur and Silicon*, **149**, 49 (1999).
- [15] M. A. A. Elneairy, F. A. Attaby, and M. S. Elsayed, *Phosphorus, Sulfur and Silicon*, **167**, 161 (2000).
- [16] M. A. A. Elneairy and A. M. Abdel-Fattah, *Phosphorus, Sulfur and Silicon*, **175**, 15 (2001).
- [17] M. A. A. Elneairy, S. M. Eldin, F. A. Attaby, and A. K. K. El-Louh, *Phosphorus, Sulfur and Silicon*, **167**, 289 (2000).
- [18] S. M. Eldin, M. A. A. Elneairy, F. A. Attaby, and A. K. K. El-Louh, *Phosphorus, Sulfur and Silicon*, **176**, 49 (2001).
- [19] A. A. Abbas, M. A. A. Elneairy, and Y. N. Mabkhot, *J. Chem. Res. (M)*, 411; (*S*), 124 (2001).
- [20] F. A. Attaby, M. A. A. Elneairy, S. M. Eldin, and A. K. K. El-Louh, *J. Chem. Chinese*, **48**, 893 (2001).
- [21] K. Hirai, Y. Iwano, T. Nishi, A. Youshida, K. Oda, and H. Koyama, U.S. Pat. 5,541,317; *C.A.*, **125**, 167960 (1996).
- [22] Y. Momose and H. Odaka, PCT Int. Appl. WO 97 36,882; *Chem. Abstr.*, **117**, 331478 (1997).
- [23] A. Youshida, H. Kogen, I. Hayakawa, et al., JP 09,292,775; *C.A.*, **127**, 234181 (1997).

- [24] J. K. Hinks, A. K. Takel, and E. Hunt, PCT Int. Appl. WO 9725,309; C.A., **127**, 161997 (1997).
- [25] J. Wrobel, Z. Li, A. Dietrich, et al., *J. Med. Chem.*, **41**, 1084 (1998).
- [26] L. Muthusubramanian, R. B. Mitra, S. Rajkumar, and V. S. S. Rao, *J. Chem. Technol. Biotechnol.*, **72**, 164 (1998).
- [27] S. I. Klein, M. Czekaj, C. J. Gardner, et al., *J. Med. Chem.*, **41**, 437 (1998).
- [28] A. Taaia, M. H. Abo-Ghalia, and O. I. Abd El-Salam, *Pharmazia*, **50**, 455 (1995), C.A., **123**, 313812 (1995).
- [29] J. Aszodi, A. Bonnet, and J. F. Chantot, EP 315, 518; C.A., **112**, 2118535 (1990).
- [30] J. Aszodi, A. Bonnet, and D. S. Gouin, EP 462, 009; C.A., **116**, 128504 (1992).
- [31] J. F. Chantot, D. S. Gouin, D. Humbert, and J. G. Teutsch, EP 520, 880; C.A., **119**, 138972 (1993).
- [32] H. Schaefer, K. Gewalt, H. Mueller, and T. Jeschke, Ger. Pat. 285, 356; C.A., **114**, 228888 (1991).
- [33] N. Mueller, W. Hallenbach, and A. Harder, Eur. Pat. Appl., EP 403 (1990); C.A., **114**, 157181 (1991).
- [34] G. Wanger, S. Leistner, H. Vieweg, and U. Krasselt, *J. Prantz. Pharmazia*, **48**, 342 (1993).
- [35] N. Biowiss, U. Krasselt, S. Leistner, and G. Wanger, *Pharmazia*, **47**, 897 (1992).
- [36] K. Meguro, H. Tawada, and H. Ikeda, Eur. Pat. Appl. EP 472 (1990), C.A., **116**, 214482 (1992).
- [37] M. Ueda, T. Gemba, M. Eigyo, and I. Adachi, EP 519, 602; C.A., **118**, 94335 (1993).
- [38] Y. Saito, M. Kitabara, M. Sakashita, K. Toyoda, and T. Shibazaki; Eur. Pat. Appl. EP 533 (1993), C.A., **119**, 117112 (1993).
- [39] A. Morimoto, K. Nishikawa, and T. Naka, EP 443, 568; C.A., **115**, 232279 (1991).
- [40] J. S. A. Brunskill, A. De, and D. F. Ewing, *J. Chem. Soc., Perkin Trans I*, 629 (1978).